Literature DB >> 26057958

Industry chases pan-genotypic and shorter HCV treatments.

Anna Azvolinsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26057958     DOI： 10.1038/nbt0615-575

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Takeda's second bet on DARTs.

Authors: 
Journal:  Nat Biotechnol       Date:  2014-11       Impact factor: 54.908

2.  FDA approvals usher in the post-interferon era in HCV.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.